(Q37981953)

26 August 2017

Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

26 August 2017

0 references

1 reference

0 references

Hui Dong

1

1 reference

PubMed ID

22311412

26 August 2017

Fu-Er Lu

series ordinal

2

1 reference

PubMed ID

22311412

26 August 2017

Li Zhao

series ordinal

3

1 reference

26 August 2017

5 February 2012

1 reference

Chinese Journal of Integrated Traditional and Western Medicine

26 August 2017

1 reference

26 August 2017

18

1 reference

26 August 2017

2

1 reference

26 August 2017

152-160

1 reference

https://scigraph.springernature.com/pub.10.1007/s11655-012-0993-2

26 August 2017

0 references

cites work

Epidemiology of non-alcoholic fatty liver disease in China.

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

GI epidemiology: nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Global challenges in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Nonalcoholic Steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Effects of cembrane-type diterpenes on proliferation of PC12 cells and their antagonistic effects on neurotoxicity induced by glutamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high-fat diet in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Hypoglycemic and insulin-sensitizing effects of berberine in high-fat diet- and streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine suppresses proinflammatory responses through AMPK activation in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Acetaldehyde-induced interleukin-1beta and tumor necrosis factor-alpha production is inhibited by berberine through nuclear factor-kappaB signaling pathway in HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine improves glucose metabolism through induction of glycolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Berberine-induced LDLR up-regulation involves JNK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Combination of simvastatin with berberine improves the lipid-lowering efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Sirtuins: novel targets for metabolic disease in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Inhibition of fatty acid synthase by polyphenols

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

A polyphenol extract modifies quantity but not quality of liver fatty acid content in high-fat-high-sucrose diet-fed rats: possible implication of the sirtuin pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Resveratrol inhibits the expression of SREBP1 in cell model of steatosis via Sirt1-FOXO1 signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Resveratrol inhibits nonalcoholic fatty liver disease in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

A herbal extract with acetyl-coenzyme A carboxylase inhibitory activity and its potential for treating metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

An active part of Artemisia sacrorum Ledeb. attenuates hepatic lipid accumulation through activating AMP-activated protein kinase in human HepG2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Transcriptome profiling analysis reveals multiple modulatory effects of Ginkgo biloba extract in the liver of rats on a high-fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

The mechanisms underlying the anti-aging activity of the Chinese prescription Kangen-karyu in hydrogen peroxide-induced human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Effects of Qushi Huayu Decoction on cathepsin B and tumor necrosis factor-alpha expression in rats with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

[Effects of Qushi Huayu Decoction in prevention and treatment of fatty liver in rats based on adiponectin-free fatty acid pathway].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Effect of Sinai san decoction on the development of non-alcoholic steatohepatitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Regulation effects on abnormal glucose and lipid metabolism of TZQ-F, a new kind of Traditional Chinese Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11655-012-0993-2

Effect of Xuezhikang Capsule on serum tumor necrosis factor-alpha and interleukin-6 in patients with nonalcoholic fatty liver disease and hyperlipidemia

21 January 2018

1 reference

12 December 2020

Evaluating the efficacy and safety of Danning Pian in the short-term treatment of patients with non-alcoholic fatty liver disease: a multicenter clinical trial.

1 reference

12 December 2020

Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion

1 reference

12 December 2020

[Thinking on integrative medicine for treatment of non-alcoholic fatty liver disease]

1 reference

12 December 2020

[Inhibitory effects of Qushi Huayu Decoction on fatty deposition and tumor necrosis factor alpha secretion in HepG2 cells induced by free fatty acid].

1 reference

12 December 2020

Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis

1 reference

12 December 2020

Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity

1 reference

12 December 2020

Pathophysiology of nonalcoholic steatohepatitis

1 reference

12 December 2020

Effectiveness of Danning Tablet in patients with non-alcoholic fatty liver of damp-heat syndrome type: a multicenter randomized controlled trial.

1 reference

12 December 2020

Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice

1 reference

12 December 2020

[Cigu Xiaozhi pills's influence on lipid peroxidation and TNF-alpha expression in liver tissues of rats with nonalcoholic steatohepatitis]

1 reference

12 December 2020

[Epidemic survey on TCM syndrome typing and preliminary discussion on TCM etiology and pathogenesis of fatty liver]

1 reference

12 December 2020

Protective effects of the Alisma orientalis extract on the experimental nonalcoholic fatty liver disease

1 reference

12 December 2020

A tumor cell growth inhibitor from Polygonum hypoleucum Ohwi

1 reference

12 December 2020

10.1007/S11655-012-0993-2

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22311412